Weiwang S. Li

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020
Tianjin, 301600, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia

Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Very-low-dose decitabine and rhTPO for thrombocytopenia in lower-risk myelodysplastic syndrome.

Journal: Annals of hematology

Published: February 14, 2026

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia.

Journal: The New England journal of medicine

Published: January 14, 2026

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.

Journal: Leukemia

Published: December 01, 2025

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.

Journal: Frontiers in immunology

Published: November 06, 2025

Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.

Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: A pilot study.

Journal: Annals of hematology

Published: October 30, 2025

Analysis of treatment response and post-discontinuation efficacy maintenance of cyclophosphamide monotherapy in T-cell large granular lymphocytic leukemia

Analysis of treatment response and post-discontinuation efficacy maintenance of cyclophosphamide monotherapy in T-cell large granular lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: August 31, 2025

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study.

Journal: Annals of medicine

Published: August 07, 2025

Single-cell analysis of immune-lineage features in T-cell large granular lymphocytic leukemia

Single-cell analysis of immune-lineage features in T-cell large granular lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 07, 2025

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.

Journal: The New England journal of medicine

Published: June 11, 2025

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.

Journal: American journal of hematology

Published: May 24, 2025

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Targeting CD38 with daratumumab for platelet transfusion refractoriness in aplastic anemia.

Journal: Blood

Published: February 27, 2025

Showing 1-12 of 21

Last Updated: 09/26/2026